Breaking News Instant updates and real-time market news.

MRK

Merck

$55.46

-0.94 (-1.67%)

, REGN

Regeneron

$338.80

6.82 (2.05%)

04:55
02/07/18
02/07
04:55
02/07/18
04:55

Drug Information Association to hold a forum

Regulatory Submissions, Info & Document Management Forum will be held in North Bethesda, MD on February 5-7.

MRK

Merck

$55.46

-0.94 (-1.67%)

REGN

Regeneron

$338.80

6.82 (2.05%)

LXRX

Lexicon

$9.78

0.46 (4.94%)

ACN

Accenture

$154.69

2.86 (1.88%)

ALPMY

Astellas Pharma

$13.25

0.125 (0.95%)

TSRO

Tesaro

$60.16

1.85 (3.17%)

NBRV

Nabriva Therapeutics

$5.68

-0.05 (-0.87%)

BMY

Bristol-Myers

$60.90

-0.06 (-0.10%)

BAYRY

Bayer

$31.20

1.335 (4.47%)

ALXN

Alexion

$114.91

2.19 (1.94%)

CAH

Cardinal Health

$65.44

1.1 (1.71%)

AMGN

Amgen

$176.65

1.9 (1.09%)

INO

Inovio

$4.22

0.12 (2.93%)

OTEX

OpenText

$35.55

-0.32 (-0.89%)

PFE

Pfizer

$35.28

0.61 (1.76%)

JNJ

Johnson & Johnson

$131.83

1.44 (1.10%)

TEVA

Teva

$20.40

0.66 (3.34%)

GSK

GlaxoSmithKline

$35.99

0.5 (1.41%)

AZN

AstraZeneca

$34.30

0.52 (1.54%)

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 12

    Feb

  • 16

    Feb

  • 16

    Feb

  • 19

    Feb

  • 26

    Feb

  • 27

    Feb

  • 27

    Feb

  • 05

    Mar

  • 08

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 17

    May

  • 23

    May

  • 28

    May

  • 23

    Oct

MRK Merck
$55.46

-0.94 (-1.67%)

01/16/18
01/16/18
UPGRADE
Target $72

Buy
Merck upgraded on earlier than expected Keytruda trial success at SunTrust
As previously reported, SunTrust analyst John Boris upgraded Merck to Buy from Hold, stating that he had expected positive data from the Keynote-189 trial but that the positive results on Progression Free Survival and Overall Survival came earlier than expected. This timing should enable Merck to maintain its first-mover advantage in first-line non-squamous Non-Small Cell Lung Cancer, or NSCLC, in the U.S. and file in the EU, Boris tells investors. He raised his price target to $72 from $54 on Merck shares, which are up $4.09, or 7%, to $62.75 in morning trading.
12/07/17
PIPR
12/07/17
NO CHANGE
PIPR
Roche lung cancer data underwhelming versus Merck's, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss says that while Roche's (RHHBY) IMpower150 data are strong and suggesting a likelihood that the combination of Tecentriq with Avastin and chemo will be approved in non-small cell lung cancer, the data also appear underwhelming compared to Merck's (MRK) KN-21G trial data. The analyst does expect Tecentriq approval in lung cancer next year and reiterates an Overweight rating on Roche. Whether KN-021G represents the "high water mark" for efficacy can only be answered following full presentation of the remaining pivotal Phase 3 trials in this setting, and until then confusion is likely to remain, Purkiss tells investors in a research note. Merck in premarket trading is up 85c to $55.20 while Roche is down 93c to $30.40.
01/16/18
RHCO
01/16/18
UPGRADE
RHCO
Buy
Merck upgraded to Buy from Hold at SunTrust
01/17/18
BMOC
01/17/18
NO CHANGE
Target $72
BMOC
Outperform
Merck price target raised to $72 from $68 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Merck to $72 from $68, keeping his Outperform rating following a 6% move higher in the stock price yesterday. The analyst says he remains bullish based on a "meaningful upside for Keytruda" and better performance from supporting drug franchises such as Gardasil. Arfaei warns however that while Keytruda has solidified its lead in non-small cell lung cancer market, it remains the company's only major growth driver while immuno oncology becomes increasingly more competitive.
REGN Regeneron
$338.80

6.82 (2.05%)

12/29/17
PIPR
12/29/17
NO CHANGE
PIPR
Biotech fund outflows continue, says Piper Jaffray
For the weekly period ending Wednesday, December 27, healthcare/biotech funds saw $338M in net outflows, representing a 0.58% decrease in assets, Piper Jaffray analyst Christopher Raymond tells investors in a research note. This marks the seventh straight negative week and the eleventh week of outflows in the past 12 weeks, the analyst points out in a research note titled "Ending 2017 on a Down Note: Biotech Outflows Continue."
01/09/18
SBSH
01/09/18
NO CHANGE
Target $388
SBSH
Neutral
Regeneron to save big from tax reform, says Citi
Citi analyst Robyn Karnauskas raised her price target for Neutral-rated Regeneron Pharmaceuticals to $388 from $380 saying the company will save big from tax reform. Regeneron noted that it will benefit from tax reform and guided for a 2018 effective tax rate of 15%-19% versus the consensus at 28%, Karnauskas tells investors in a research note. She notes that the company plans to reinvest much of the savings.
12/18/17
MSCO
12/18/17
NO CHANGE
MSCO
Morgan Stanley sees opportunities in biotech amid 'limited' investor conviction
With clinical catalysts in large-cap Biotechnology limited to only five key Phase III readouts - three of which are from Alexion (ALXN) - investors are describing their 2018 picks in the space as the "least worst" of the group, according to Morgan Stanley analyst Matthew Harrison. However, he believes this lack of conviction creates real opportunity for outsized moves in 2018, with Amgen (AMGN) identified by Harrison as the biggest potential beneficiary of M&A given "its likely newfound access" to about $39B in offshore cash. Other biotech names the analyst highlights on the up side include Biogen (BIIB), BioMarin (BMRN), Biohaven (BHVN) and Sarepta (SRPT). Meanwhile, Harrison highlights his concerns about potential downside for BioVerativ (BIVV) and Innoviva (INVA), on both of which he keeps Underweight ratings.
12/28/17
ARGS
12/28/17
NO CHANGE
Target $470
ARGS
Buy
Regeneron price target lowered to $470 from $540 at Argus
Argus analyst Jasper Hellweg lowered his price target on Regeneron (REGN) to $470 to reflect some of the recent weakness in the stock, but keeps his Buy rating. Hellweg says that while the company's growth has slowed in recent years, it continues to benefit from sales of Eylea, collaboration agreements with Sanofi (SNY) and Bayer (BAYRY) as well as a strong new product pipeline.
LXRX Lexicon
$9.78

0.46 (4.94%)

03/07/17
SBSH
03/07/17
NO CHANGE
Target $28
SBSH
Buy
Lexicon price target raised to $28 from $24 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Lexicon Pharmaceuticals to $28 saying the company's potential in diabetes remains underappreciated. Management's commentary on sotagliflozin should re-assure investors who remain unconvinced about the T1D thesis, Nochomovitz tells investors in a post-earnings research note. He keeps a Buy rating on Lexicon.
10/02/17
WEDB
10/02/17
NO CHANGE
WEDB
Wedbush adding Capital One, removing Lexicon from Best Ideas List
Wedbush is removing Lexicon (LXRX) from its Best Ideas List because the main potential catalysts for 2017 have been announced and it does not see material announcements in the remainder of 2017 but look to 2018 for material U.S. regulatory catalysts. Additionaly, it is adding Capital One (COF) as an Underperform to the Best Ideas List. The firm is not positioning Capital One as an absolute "alpha-short", but says the focus is its performance relative to its credit card peers and banks in the S&P 500 bank index.
09/15/17
SBSH
09/15/17
NO CHANGE
Target $28
SBSH
Buy
Lexicon sold off on increased competition concerns, says Citi
Citi analyst Yigal Nochomovitz attributes the 10% selloff yesterday in shares of Lexicon Pharmaceuticals to increased competition after the 24-week results from the Depict1 trial for dapagliflozin in type 1 diabetes were presented. The data are broadly in line with what we've seen from sotagliflozin, suggesting a similar efficacy and safety profile between the two drugs, Nochomovitz tells investors in a research note. He reminds investors that he always expected competition in the adjunctive type 1 diabetes space, and currently models 35% peak share for sotagliflozin, which he thinks leaves "plenty of room for another SGLT inhibitor." The analyst has a Buy rating on Lexicon with a $35 price target.
09/13/17
JPMS
09/13/17
NO CHANGE
JPMS
Neutral
Editorial published with Lexicon data reads cautiously, says JPMorgan
JPMorgan analyst Jessica Fye noted that full results for Lexicon Pharmaceuticals' Phase 3 inTandem3 study were released in the New England Journal of Medicine, accompanied by an editorial that reads cautiously on associated diabetic ketoacidosis. The comments from the editorial give her further pause on overall DKA risk and she thinks the relative risk in pumps patients may be at a threshold where physicians and the FDA could be cautious, she tells investors. Fye keeps a Neutral rating on Lexicon shares, which have fallen by more than 9% following the publication.
ACN Accenture
$154.69

2.86 (1.88%)

02/05/18
MSCO
02/05/18
UPGRADE
Target $180
MSCO
Overweight
Morgan Stanley double upgrades IT Services, moves Accenture to Overweight
Morgan Stanley analyst Brian Essex upgraded Accenture (ACN) to Overweight and raised his price target for the shares to $180 from $159. The analyst, following his firm's chief investment officer survey, believes the secular shift toward digital and cloud adoption is in the early stages. As such, Essex double upgraded his view on the IT Services industry to Attractive from Cautious. Vendors with strong positioning in consulting and system integration and next-gen applications should take market share, the analyst tells investors in a research note on the sector. Along with his upgrade of Accenture, the Essex highlights IBM (IBM) and Capgemini (CGEMY) as names poised to benefit relative to peers. He also raised his price target for Cognizant shares to $84 from $77.
01/02/18
FBCO
01/02/18
NO CHANGE
Target $165
FBCO
Neutral
Accenture price target raised to $165 from $134 at Credit Suisse
Credit Suisse analyst Charles Brennan raised his price target for Accenture to $165 from $134 after the company reported stronger than expected results. The analyst reiterates a Neutral rating on the shares.
12/27/17
BARD
12/27/17
NO CHANGE
Target $162
BARD
Neutral
Accenture estimates lowered to reflect higher expected tax rate at Baird
Baird analyst David Koning lowered his estimates on Accenture to reflect a higher expected tax rate beginning in 2019. He sees Street estimate being lowered, which should keep the stock soft near-term. Koning sees the risk/reward as balanced and reiterated his Neutral rating and $162 price target on Accenture shares.
02/05/18
MSCO
02/05/18
UPGRADE
MSCO
Overweight
Accenture upgraded to Overweight from Equal Weight at Morgan Stanley
ALPMY Astellas Pharma
$13.25

0.125 (0.95%)

TSRO Tesaro
$60.16

1.85 (3.17%)

01/16/18
CANT
01/16/18
NO CHANGE
Target $31
CANT
Overweight
Tesaro update could drive sales upside for Heron, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen notes that Tesaro (TSRO) announced that it had modified the warnings section of the package insert for Varubi to include post-marketing reports of anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions. This could mean upside to sales for Heron Therapeutics' (HRTX) Cinvanti, Chen tells investors in a research note. The analyst thinks the drug's peak sales potential are still underappreciated. She keeps an Overweight rating on Heron with a $31 price target.
01/16/18
COWN
01/16/18
NO CHANGE
Target $40
COWN
Outperform
Tesaro Varubi setback an incremental positive for Heron, says Cowen
Cowen analyst Boris Peaker said the setback for Tesaro's (TSRO) Varubi regarding its label change is an incremental positive for Heron Therapeutics' (HRTX) Cinvanti. The analyst noted Heron launched Cinvanti for a similar indication but without anaphylaxis risk in the label. Peaker reiterated his Outperform rating and $40 price target on Heron Therapeutics shares.
01/18/18
FBCO
01/18/18
NO CHANGE
Target $150
FBCO
Outperform
Tesaro price target lowered to $150 from $190 at Credit Suisse
Credit Suisse analyst Alethia Young lowered her price target for Tesaro to $150 from $190 to include lower than forecasted Zejula or Varubi sales or clinical setbacks. The analyst reiterates an Outperform rating on the shares.
01/16/18
MZHO
01/16/18
NO CHANGE
Target $28
MZHO
Buy
Cinvanti competitor safety issues positive for Heron Therapeutics, says Mizuho
Mizuho analyst Difei Yang notes that Tesaro (TSRO) announced a modification to the Warning section in the prescribing information of Varubi IV - a direct competitor to Cinvanti - following a high rate of anaphylaxis associated with the drug. The analyst sees this development as potentially very positive for Heron Therapeutics (HRTX) given the strong safety profile of Cinvanti in clinical studies. Yang reiterates a Buy rating and $28 price target on Heron's shares.
NBRV Nabriva Therapeutics
$5.68

-0.05 (-0.87%)

01/18/18
MSCO
01/18/18
INITIATION
Target $10
MSCO
Overweight
Nabriva Therapeutics initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Andrew Berens started Nabriva Therapeutics yesterday with an Overweight rating and $10 price target.
09/18/17
WEDB
09/18/17
NO CHANGE
Target $21
WEDB
Outperform
Wedbush calls Nabriva data 'giant leap,' ups target to $21
Wedbush analyst Robert Driscoll raised his price target for Nabriva Therapeutics to $21 from $13 after the company's Phase 3 study for lefamulin against pneumonia met the primary endpoint. The analyst calls the data a "giant leap" for lefamulin. He has an Outperform rating on Nabriva. The shares in midday trading are up 37% to $9.43.
09/18/17
RHCO
09/18/17
NO CHANGE
Target $24
RHCO
Buy
Nabriva Therapeutics price target raised to $24 from $20 at SunTrust
SunTrust analyst Edward Nash raised his price target for Nabriva Therapeutics to $24 saying this morning's data verify lefamulin as a novel antibiotic for community acquired bacterial pneumonia. The analyst keeps a Buy rating on the shares.
11/16/17
HCWC
11/16/17
NO CHANGE
Target $20
HCWC
Buy
Nabriva shares still look 'significantly undervalued,' says H.C. Wainwright
H.C. Wainwright analyst Ed Arce says that with Leap 2 trial enrollment completion in Q4 and the top-line results in the spring of 2018, shares of Nabriva Therapeutics continue to look "significantly undervalued." The analyst continues to expect favorable results from the pivotal study in moderate to severe community-acquired bacterial pneumonia patients. He affirms a Buy rating on Nabriva with a $20 price target.
BMY Bristol-Myers
$60.90

-0.06 (-0.10%)

11/30/17
GABE
11/30/17
NO CHANGE
Target $133
GABE
Buy
Incyte a top biotech pick for 2018 at Gabelli
Gabelli analyst Jing He highlighted Incyte as his top biotech pick for 2018 telling investors shares are undervalued and should benefit from the Epa melanoma data readout in first half 2018. The analyst said shares are trading near a 52-week low despite progress in the pipeline and believes competitors Bristol-Myers (BMY) and NewLink's (NLNK) IDO inhibitors are a few years behind Epa in development. Further, as tax reform gains more clarity, He believes M&A oncology deals could pickup and views Incyte as an attractive takeover target. Jing He rates Incyte a Buy with a $133 price target.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $88
JEFF
Buy
Bristol-Myers makes sense as potential Nektar acquirer, says Jefferies
Jefferies analyst David Steinberg believes Bloomberg's report that Nektar Therapeutics (NKTR) is exploring strategic options is not surprising. For many years Nektar's most important assets were out licensed, but that is no longer the case, Steinberg tells investors in a research note. The company's current partner Bristol-Myers Squibb (BMY) would make sense to be on the short list of potential acquirer, the analyst adds. Steinberg keeps a Buy rating on Nektar with an $88 price target.
02/06/18
LEER
02/06/18
NO CHANGE
Target $76
LEER
Outperform
Bristol-Myers price target raised to $76 from $71 at Leerink
Leerink analyst Seamus Fernandez raised his price target for Bristol-Myers to $76 from $71 and increased Opdivo and Yervoy estimates following positive CM-227 PFS Topline. The analyst reiterates an Outperform rating on the shares.
BAYRY Bayer
$31.20

1.335 (4.47%)

11/15/17
MSCO
11/15/17
NO CHANGE
Target $103
MSCO
Overweight
Loxo Oncology partnership with Bayer better than recognized, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison thinks Loxo Oncology's (LOXO) partnership with Bayer (BAYRY) is a smart move and points to two key aspects of the deal that are being underappreciated. Namely, the deal offsets the risk of a slow TRK launch while he also believes strategic optionality is still intact as Loxo maintains two fully owned program, Harrison tells investors. Harrison maintains an Overweight rating on Loxo with a $103 price target. The stock slid about 4% yesterday to close at $79.84 after the Bayer deal was announced.
11/16/17
JEFF
11/16/17
NO CHANGE
JEFF
Buy
Jefferies names Roche new top global pick in Pharmaceuticals
Jefferies analyst Jeffrey Holford names Roche (RHHBY) his new "Top Pick Globally" in Pharmaceuticals following the strong share performance of his previous top pick for 2017, AbbVie (ABBV). The analyst believes the company's growth outlook is better than many investors think. Roche is nearing sentiment lows and investors "need to look hard at the replacement power" offered by assets Tecentriq, Ocrevus, Gazyva, ACE910 and Perjeta, Holford tells investors in a research note. Following Roche, the analyst has the highest conviction on Novartis (NVS), Bayer (BAYRY), AbbVie, Johnson & Johnson (JNJ), Zoetis (ZTS) and Eli Lilly (LLY). His least preferred stocks in Pharmaceuticals are Merck (MRK), Novo Nordisk (NVO) and AstraZeneca (AZN).
12/29/17
JPMS
12/29/17
NO CHANGE
JPMS
Roche added to Analyst Focus List at JPMorgan
JPMorgan analyst Richard Vosser added Roche (RHHBY) to his firm's Analyst Focus List and keeps an Overweight rating on the shares with a SFR 300 price target. The analyst sees Roche as having the most significant earnings upside potential of any of the European large cap pharma stocks in 2018. He believes the potential of the company's pipeline is being underappreciated at current share levels. His top picks for 2018 are Roche and Bayer (BAYRY).
ALXN Alexion
$114.91

2.19 (1.94%)

02/02/18
DBAB
02/02/18
NO CHANGE
Target $163
DBAB
Buy
Deutsche Bank remains bullish on Alexion ahead of data
The upcoming read-outs from two ongoing Phase 3 trials in paroxysmal nocturnal hemoglobinuria comparing ALXN1210 versus Soliris will be critical to the success of Alexion shares both in the near and long-term, Deutsche Bank analyst Andrew Peters tells investors in a research note. The analyst remains bullish on the stock into the read-outs saying the data suggest a highly effective clinical profile. He keeps a Buy rating on Alexion with a $163 price target.
01/04/18
01/04/18
DOWNGRADE
Target $130

Outperform
Alexion downgraded to Outperform on valuation at Raymond James
As previously reported, Raymond James downgraded Alexion to Outperform from Strong Buy and lowered its price target to $130 from $178. Analyst Laura Chico believes risk/reward is more limited at current levels, particular when tax reform is a headwind for the company.
01/18/18
FBCO
01/18/18
INITIATION
Target $147
FBCO
Outperform
Alexion assumed with an Outperform at Credit Suisse
Credit Suisse analyst Martin Auster assumed coverage of Alexion Pharmaceuticals with an Outperform rating and $147 price target. The analyst views the stock as well positioned for 2018 given his expectations that Solaris will gain momentum in generalized myasthenia gravis.
02/05/18
EVER
02/05/18
UPGRADE
EVER
Outperform
Alexion upgraded to Outperform from In Line at Evercore ISI
CAH Cardinal Health
$65.44

1.1 (1.71%)

11/30/17
JEFF
11/30/17
NO CHANGE
JEFF
Jefferies sees drugstore sentiment improving with no Amazon news
Investors were anticipating an announcement from Amazon.com (AMZN) regarding a pharmacy strategy around Thanksgiving due to recent media reports and the resulting sell-side speculation, Jefferies analyst Brian Tanquilut tells investors in a research note. With no Amazon pharmacy entry announced one week removed from the holiday, the analyst believes investor sentiment over the drug supply chain may gradually improve, at least in the near-term. He notes that the price-to-earnings multiples of Walgreens Boots Alliance (WBA) and CVS Health (CVS) have already declined amid speculation of an Amazon entry. Tanquilut acknowledges, however, that the Amazon overhang will not completely go away. The analyst has Buy ratings on UnitedHealth (UNH) and Walgreens, and Hold ratings on AmerisourceBergen (ABC), Cardinal Health (CAH), CVS and McKesson (MCK).
01/04/18
EVER
01/04/18
INITIATION
Target $67
EVER
In Line
Cardinal Health initiated with an In Line at Evercore ISI
Evercore ISI started Cardinal Health with an In Line rating and $67 price target.
12/04/17
LEER
12/04/17
NO CHANGE
LEER
Amazon entry into healthcare markets focused on medical supplies, says Leerink
Leerink analyst David Larsen says that his recent research around Amazon's (AMZN) licensing activity has shown that the company's entry into healthcare markets is, at least for now, focused on medical supplies and devices rather than pharmaceuticals. The analyst believes Owens & Minor (OMI), Cardinal Health (CAH) and Henry Schein (HSIC) are most exposed but that it will take several years for Amazon Business to scale up manufacturer supply relationships to take significant share. Although the top and bottom line impact may be small over the next year or two, Larsen remains cautious on the group as multiples continue to reflect the Amazon threat as well as pricing and volume headwinds.
12/04/17
DBAB
12/04/17
INITIATION
Target $64
DBAB
Hold
Cardinal Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Glen Santangelo started Cardinal Health with a Hold rating and $64 price target. The analyst believes uncertainty around drug pricing and the potential for integration risk with Cordis and the Patient Recovery acquisitions warrant a "more prudent approach" to the shares.
AMGN Amgen
$176.65

1.9 (1.09%)

02/02/18
BMOC
02/02/18
NO CHANGE
Target $202
BMOC
Market Perform
Amgen price target raised to $202 from $192 at BMO Capital
BMO Capital analyst M. Ian Somaiya raised his price target on Amgen to $202 after a "mixed" Q4 earnings report that showed soft top line and heightened uncertainty for 2018 guidance. The analyst notes that the $10B stock buyback will alleviate some of the uncertainty around the outcome of Sandoz litigation and give the company some time to relaunch Repatha and launch Aimovig. Somaiya keeps his Market Perform rating on Amgen.
01/31/18
JEFF
01/31/18
NO CHANGE
JEFF
Jefferies sees neutral impact on Biotech from State of the Union
Jefferies analyst Michael Yee sees a net neutral impact on Biotech stocks from President Trump's State of the Union speech last night. During the speech, Trump made comments about making lower drug prices a "priority" for the year, Yee tells investors in a research not titled "Drug Pricing Comments Not New or Surprising - But a Reminder of Rhetoric." The President, however, also commented on broader access to novel clinical trial drugs, Yee points out. After a "strong biotech rally" in January, the analyst assumes the sector, "at some point," will have some relative near-term pullback either on uncertainty about Trump commentary or some consolidation. Some of the analyst's Buy-rated names include AbbVie (ABBV), Amgen (AMGN), Eli Lilly (LLY) and Gilead Sciences (GILD).
02/05/18
02/05/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) downgraded to Market Perform from Outperform at Keefe Bruyette, to Neutral from Buy at Citi, to Underperform from Outperform at RBC Capital, to Underweight from Neutral at JPMorgan, and two notches to Underweight from Overweight at Morgan Stanley. 2. Dick's Sporting (DKS) downgraded to Underweight from Equal Weight at Barclays with analyst Matthew McClintock saying sentiment on the shares have improved over the past month under the narrative that Dick's could become the next Best Buy (BBY). 3. Amgen (AMGN) downgraded to Neutral from Overweight at Atlantic Equities with analyst Steve Chesney citing relative valuation and more balanced risk/reward on Repatha's commercial trajectory and the of legacy biologics given biosimilar, branded and IP risks. 4. Marathon Petroleum (MPC) and MPLX (MPLX) were downgraded to Hold from Buy at Jefferies. 5. VMware (VMW) downgraded to Neutral from Buy at Citi with analyst Walter Pritchard saying he sees "no easy deal" for Dell and expects the overhang to cap VMware shares around the $138 level. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/05/18
ATLE
02/05/18
DOWNGRADE
ATLE
Neutral
Amgen downgraded to Neutral from Overweight at Atlantic Equities
Atlantic Equities analyst Steve Chesney downgraded Amgen to Neutral citing relative valuation and more balanced risk/reward on Repatha's commercial trajectory and the of legacy biologics given biosimilar, branded and IP risks. Chesney cut Amgen estimates by 5%-7% on lower Repatha and said he sees a dearth of new clinical data and commercial launches skewed to second half 2018.
INO Inovio
$4.22

0.12 (2.93%)

10/18/17
10/18/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aaron's (AAN) initiated with a Neutral at Janney Capital. 2. Inovio (INO) initiated with an Outperform at RBC Capital. 3. Carrizo Oil & Gas (CRZO) reinstated with a Neutral at Goldman Sachs. 4. Goodrich Petroleum (GDP) assumed with a Buy at Seaport Global. 5. Krystal Biotech (KRYS) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/12/17
MAXM
09/12/17
NO CHANGE
MAXM
Inovio data positive, says Maxim
Maxim analyst Jason McCarthy says that the data on Inovio's (INO) INO-5150 for prostate cancer indicates that the drug "holds promise." He thinks that the company may find a new partner to replace Roche (RHHBY), and he keeps a $12 price target and a Buy rating on the shares.
10/18/17
RBCM
10/18/17
INITIATION
RBCM
Outperform
Inovio initiated with an Outperform at RBC Capital
RBC Capital analyst Matthew Eckler initiated Inovio with an Outperform and $11 price target saying Phase III asset VGX-3100 has potential to be the first non-surgical approach for the treatment of HPV-driven cervical pre-cancers. Eckler also believes Inovio's early immuno-oncology platform also offer significant upside if any of the ongoing Phase1/Phase trials generate encouraging results.
10/06/17
SBSH
10/06/17
NO CHANGE
Target $10
SBSH
Buy
Zika data supportive of Inovio's platform, says Citi
The Phase 1 trial data for the company's Zika vaccine, published this week in the New England Journal of Medicine, are supportive for Inovio's platform beyond the immunogenicity data, Beatty tells investors in a research note. Inovio's platform may have the potential to generate functional antibodies in nearly 100% of people receiving a vaccine, which could also be useful in oncology if good antigen and tumor matches are made, Beatty adds. He believes the data support the view that Inovio is a leader in infectious disease vaccines. The analyst keeps a Buy rating on the shares with a $10 price target.
OTEX OpenText
$35.55

-0.32 (-0.89%)

11/22/17
RAJA
11/22/17
NO CHANGE
Target $40
RAJA
Outperform
Raymond James remains bullish on OpenText despite competitor downgrade
Raymond James analyst Steven Li notes that a competitor downgraded OpenText this morning to an Underperform rating, saying Constellation Software has a much stronger balance sheet. The analyst argues that it is "stating the obvious," given that OpenText just made the largest acquisition in its history. This logic does not hold historically, he notes. While Li acknowledges that Constellation Software has much higher return on capital, and may have better growth and cash return prospects, he points out that its competitor report does not highlight the recent turn in organic growth. The analyst reiterates an Outperform rating and $40 price target on OpenText's shares.
07/27/17
RILY
07/27/17
DOWNGRADE
Target $7.1
RILY
Neutral
Guidance Software downgraded to Neutral from Buy at B. Riley
B. Riley analyst Kevin Liu downgraded Guidance Software (GUID) to Neutral and lowered his price target for the shares to $7.10 from $9 after the company agreed to be acquired by OpenText (OTEX).
11/22/17
MACQ
11/22/17
DOWNGRADE
Target $31.5
MACQ
Underperform
OpenText downgraded to Underperform from Neutral at Macquarie
Macquarie analyst Gus Papageorgiou downgraded OpenText to Underperform and lowered its price target to $31.50 from 34.50. The analyst said OpenText has highly recurring and profitable operations but poor returns on capital and limited growth due to a leveraged balance sheet.
02/01/18
MUFG
02/01/18
NO CHANGE
Target $50
MUFG
Overweight
OpenText price target raised to $50 from $40 at MUFG
MUFG analyst Stephen Bersey raised his price target for OpenText to $50 after the company "handily beat" his estimates for Q2. OpenText "had a great quarter," Bersey tells investors in a post-earnings research note. The analyst keeps an Overweight rating on the shares.
PFE Pfizer
$35.28

0.61 (1.76%)

01/29/18
RHCO
01/29/18
NO CHANGE
Target $40
RHCO
Hold
Pfizer price target raised to $40 from $33 at SunTrust
SunTrust analyst John Boris raised his price target on Pfizer to $40 and kept his Hold rating ahead of this week's earnings. The analyst attributes the price outlook revision to the positive impact of the tax changes, but notes that "transformative large-scale M&A" is needed to bring about return to "robust" long-term growth.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
11/14/17
WELS
11/14/17
NO CHANGE
Target $12
WELS
Outperform
Pfizer ADHD drug supply shortage is positive for Neos, says Wells Fargo
Wells Fargo analyst David Maris says Pfizer (PFE) has sent a letter on physicians dated November 8th telling them of a supply shortage for its liquid and chewable methylphenidate ADHD products. Maris says Pfizer's product is a direct competitor of Neos' (NEOS) recently-launched Cotempla XR-ODT, adding Neos will benefit from having its primary competition in the alternative dose market facing a shortage. The analyst says Cotempla XR-ODT, launched in September, is off to a very strong start, keeping his Outperform rating with a $12 price target on Neos.
JNJ Johnson & Johnson
$131.83

1.44 (1.10%)

01/04/18
RBCM
01/04/18
NO CHANGE
Target $54
RBCM
Outperform
Pacira price target raised to $54 from $50 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Pacira (PCRX) to $54 and kept his Outperform rating. Stanicky says his focus is on the company's expected pre-announcement for Q4 this week and his upcoming discussion with CEO Dave Stack on Monday regarding changes from CMS around unbundling of payments that could represent a game changing opportunity for the company's EXPAREL. The analyst notes that traction is building around Pacira's relationship with Johnson & Johnson (JNJ) on the ortho selling side, which marks about half of its revenue.
02/06/18
WELS
02/06/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson talc litigation concerns appear overblown, says Wells Fargo
Wells Fargo analyst Lawrence Biegelsen says Johnson & Johnson shares were down partly due to concerns about ongoing litigation over allegations that its talcum power products are unsafe for use because they contain asbestos which can cause mesothelioma. Based on prior high-profile product liability cases in the drug and device sectors, the analyst believes any potential settlement would be manageable for Johnson & Johnson. He reiterates an Outperform rating and $160 price target on the shares.
01/18/18
MSCO
01/18/18
NO CHANGE
Target $157
MSCO
Equal Weight
Zytiga ruling a headwind, but doesn't change J&J thesis, says Morgan Stanley
Morgan Stanley analyst David Lewis noted that Johnson & Johnson suffered an adverse Zytiga IPR ruling, which he calls an incremental headwind. However, he added that a possible earlier generic Zytiga entry is irrelevant to his net present value for J&J shares and doesn't change his view that its Pharma growth accelerates in 2018. Lewis keeps an Equal Weight rating and $157 price target on J&J shares.
01/02/18
01/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Neutral from Overweight at JPMorgan with analyst Michael Weinstein saying he sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. 2. PG&E (PCG) downgraded to Sell from Neutral at Guggenheim and to Neutral from Buy at Goldman Sachs. Goldman analyst Michael Lapides saying resolution of claims from the California wildfires, if inverse condemnation is applied, could take years and "cash flow/balance sheet impacts could prove significant still." 3. Allstate (ALL) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying the company's margin expansion story has played out. 4. Cabot Oil & Gas (COG) downgraded two notches to Underperform from Outperform at Raymond James with analyst John Freeman citing valuation after "considerable" 2017 share outperformance. 5. Windstream (WIN) downgraded to Underweight from Neutral at JPMorgan with analyst Philip Cusick saying he sees fundamental business challenges continuing in both the near and long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TEVA Teva
$20.40

0.66 (3.34%)

02/05/18
STFL
02/05/18
NO CHANGE
Target $20
STFL
Buy
Corcept price target lowered to $20 after 'surprise' Korlym ANDA at Stifel
Stifel analyst Adam Walsh lowered his FY21 and FY22 U.S. Korlym estimates after Corcept (CORT) announced that Teva (TEVA) submitted an ANDA for a generic version of the drug in the U.S. He said he was surprised by the timing of the ANDA, which challenges two Orange Book listed patents. Walsh, who also reduced his U.S. estimates for the second-gen Korlym replacement, relacorilant, lowered his price target on Corcept to $20 from $25, though he keeps a Buy rating on the stock.
02/02/18
BTIG
02/02/18
DOWNGRADE
Target $17
BTIG
Sell
Teva downgraded to Sell from Neutral at BTIG
As reported earlier, BTIG analyst Timothy Chung downgraded Teva to Sell from Neutral with a price target of $17. Chung attributes the rating change to expectations of continued decline in U.S. generics segment amid price erosion and competition in products such as Concerta, sales declines for Copaxone from generic competition, and rising interest rates along with credit rating downgrade leading to "substantially" higher borrowing costs.
02/02/18
BTIG
02/02/18
DOWNGRADE
BTIG
Sell
Teva downgraded to Sell from Neutral at BTIG
02/01/18
WELS
02/01/18
NO CHANGE
WELS
Underperform
Wells says Teva equity holders getting 'short end' of deal as debt gets amended
Wells Fargo analyst David Maris noted that Teva reports it has amended its USD and JPY term loan and revolving credit facilities, though it did not announce whether this change came with any payment to debt holders. Based on his talks with his debt counterparts at the firm, Maris believes the amendment cost Teva approximately 20-30 bps on the about $3B in related debt. Equity holders are getting the "short end" of this deal, as Teva has agreed to suspend dividends and as future debt maturity moves he suspects it will be done at a higher rate than Teva's current one, Maris tells investors. He maintains his Underperform rating on Teva shares.
GSK GlaxoSmithKline
$35.99

0.5 (1.41%)

01/22/18
WELS
01/22/18
NO CHANGE
WELS
Underperform
Teva can't afford more pipeline setbacks, says Wells Fargo
After Teva (TEVA) reported that its Phase 3 registration study evaluating subcutaneously administered reslizumab in a pre-filled syringe did not meet its primary endpoint, Wells Fargo analyst David Maris said he believes this puts Teva at a disadvantage versus peers AstraZeneca (AZN) and GlaxoSmithKline (GSK) at a time when Teva cannot afford more pipeline setbacks. Subcutaneous reslizumab was not a major focus, but the news is still "another disappointment," said Maris, who keeps an Underperform rating on Teva shares.
01/16/18
LEHM
01/16/18
UPGRADE
LEHM
Overweight
GlaxoSmithKline upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Emmanuel Papadakis upgraded GlaxoSmithKline to Overweight from Equal Weight and raised his price target for the shares to GBP 16.50 from GBP 14.50. The analyst believes concerns are now reflected in the valuation and consensus expectations while HIV and shingles offer "sustainable drivers of mid-term growth."
01/16/18
LEHM
01/16/18
UPGRADE
LEHM
Overweight
GlaxoSmithKline upgraded to Overweight from Equal Weight at Barclays
01/22/18
WBLR
01/22/18
NO CHANGE
WBLR
Outperform
Dynavax has sold off 30% since Heplisav approval, says William Blair
Dynavax (DVAX) shares have pulled back about 30% since the U.S. approval of Heplisav, the first and only two-dose hepatitis B vaccine that has demonstrated "superiority in efficacy and comparability" in safety to the standard of care, GlaxoSmithKline's (GSK) Engerix-B, William Blair analyst Katherine Xu tells investors in a research note. The analyst attributes the selloff to Dynavax electing to launch Heplisav on its own and the Street having insufficient confidence in the launch. She believes Heplisav has peak U.S. sales prospects of $600M and "provides a valuation floor." Xu also sees catalysts on the oncology side of the business. She maintains an Outperform rating on Dynavax with a $40 per share fair value estimate.
AZN AstraZeneca
$34.30

0.52 (1.54%)

01/02/18
ADAM
01/02/18
NO CHANGE
Target $77
ADAM
Buy
ANI Pharmaceuticals best positioned in emerging generics space, says Canaccord
Canaccord analyst Dewey Steadman said ANI Pharmaceuticals (ANIP) is one of the best positioned names in the emerging generics space. He noted the company has a basket of additional branded tail assets from its AstraZeneca (AZN) acquisitions, additional cash on hand and credit facilities for future transactions, and a solid core business. Steadman reiterated his Buy rating and raised his price target to $77 from $75 on ANI Pharmaceuticals shares.
12/29/17
12/29/17
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. AstraZeneca (AZN) upgraded to Overweight from Neutral at JPMorgan with analyst James Gordon saying the company's "superior medium-term growth outlook," which is twice the peer average, warrants a 25% sector premium. 2. PriceSmart (PSMT) upgraded to Outperform from Market Perform at IFS Securities. 3. Novo Nordisk (NVO) upgraded to Neutral from Underweight at JPMorgan with analyst Richard Vosser saying he expects "strong" oral semaglutide Phase III newsflow in 2018. 4. Syntel (SYNT) downgraded to Underperform from Market Perform at Wells Fargo with analyst Ed Caso saying he sees the company's "weak" positioning for the ongoing shift in information technology demand from "legacy" low-cost offshore-centric software services to more onshore-necessary "digital" solutions as dragging down its growth and margins. 5. RioCan REIT downgraded to Sector Perform from Outperform at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/29/17
JPMS
12/29/17
UPGRADE
JPMS
Overweight
AstraZeneca upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Gordon upgraded AstraZeneca to Overweight and raised his price target for the shares to 55 pounds from 48 pounds. The company's "superior medium-term growth outlook," which is twice the peer average, warrants a 25% sector premium, Gordon tells investors in a research note. He believes downside risk around the Mystic trial failure and "overly high base business expectations" have now lessened with consensus earnings forecasts declining 15%. The analyst expects AstraZeneca to return to sales growth in 2018, even without further immuno-oncology trial success. Astra has 10 Phase III readouts, with fairly low expectations across the board, Gordon argues.

TODAY'S FREE FLY STORIES

A

Agilent

$62.79

-0.24 (-0.38%)

, ABT

Abbott

$61.93

0.19 (0.31%)

04:55
06/23/18
06/23
04:55
06/23/18
04:55
Conference/Events
American Diabetes Association to hold a conference »

78th Scientific Sessions…

A

Agilent

$62.79

-0.24 (-0.38%)

ABT

Abbott

$61.93

0.19 (0.31%)

AKCA

Akcea Therapeutics

$26.24

0.4 (1.55%)

AMGN

Amgen

$184.86

-1.14 (-0.61%)

AZN

AstraZeneca

$35.06

-0.095 (-0.27%)

BAYRY

Bayer

$0.00

(0.00%)

CL

Colgate-Palmolive

$64.63

1.15 (1.81%)

DXCM

DexCom

$99.52

-0.2 (-0.20%)

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

IRWD

Ironwood

$19.35

0.74 (3.98%)

JNJ

Johnson & Johnson

$122.81

1.36 (1.12%)

MDT

Medtronic

$86.80

0.51 (0.59%)

MNKD

MannKind

$1.98

0.02 (1.02%)

WAKE

Wake Forest Bancshares Inc.

$0.00

(0.00%)

VLRX

Valeritas

$1.39

0.035 (2.58%)

TNDM

TNDM

SNY

Sanofi

$39.98

0.96 (2.46%)

SIEGY

Siemens

$0.00

(0.00%)

SENS

Senseonics

$4.76

-0.2 (-4.03%)

REGN

Regeneron

$331.82

2.81 (0.85%)

PODD

Insulet

$97.37

0.5697 (0.59%)

NVO

Novo Nordisk

$46.84

0.435 (0.94%)

MRK

Merck

$61.46

0.295 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 28

    Jun

  • 02

    Jul

  • 06

    Jul

  • 12

    Jul

  • 17

    Jul

  • 18

    Jul

  • 11

    Aug

  • 27

    Aug

  • 30

    Aug

  • 10

    Sep

  • 06

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 28

    Jan

  • 22

    Mar

ARRY

Array BioPharma

$19.37

-0.19 (-0.97%)

04:55
06/23/18
06/23
04:55
06/23/18
04:55
Conference/Events
Array BioPharma to hold a conference call »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 30

    Jun

  • 30

    Jun

ICE

IntercontinentalExchange

$74.81

-0.11 (-0.15%)

04:55
06/23/18
06/23
04:55
06/23/18
04:55
Conference/Events
IntercontinentalExchange management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

AMGN

Amgen

$184.86

-1.14 (-0.61%)

, ARRY

Array BioPharma

$19.37

-0.19 (-0.97%)

04:55
06/23/18
06/23
04:55
06/23/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO World Congress on…

AMGN

Amgen

$184.86

-1.14 (-0.61%)

ARRY

Array BioPharma

$19.37

-0.19 (-0.97%)

BAYRY

Bayer

$0.00

(0.00%)

HALO

Halozyme

$18.07

-0.52 (-2.80%)

INCY

Incyte

$74.02

1.55 (2.14%)

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

MRK

Merck

$61.46

0.295 (0.48%)

SHPG

Shire

$161.73

-0.7 (-0.43%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$39.98

0.96 (2.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 28

    Jun

  • 30

    Jun

  • 30

    Jun

  • 10

    Sep

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 21

    Dec

  • 28

    Jan

  • 22

    Mar

NWN

Northwest Natural Gas

$62.63

0.075 (0.12%)

, PCG

PG&E

$42.98

2.44 (6.02%)

18:17
06/22/18
06/22
18:17
06/22/18
18:17
Hot Stocks
Northwest Natural to sell Gill Ranch Storage to SENSA Holdings »

NW Natural (NWN)…

NWN

Northwest Natural Gas

$62.63

0.075 (0.12%)

PCG

PG&E

$42.98

2.44 (6.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ORLY

O'Reilly Automotive

$285.90

-1.18 (-0.41%)

18:03
06/22/18
06/22
18:03
06/22/18
18:03
Hot Stocks
O'Reilly Automotive's O'Reilly sells 19,250 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJI

South Jersey Industries

$33.15

0.02 (0.06%)

17:46
06/22/18
06/22
17:46
06/22/18
17:46
Hot Stocks
South Jersey Industries announces approval of Elizabethtown Gas purchase »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAAS

AquaVenture

$15.36

0.12 (0.79%)

17:27
06/22/18
06/22
17:27
06/22/18
17:27
Hot Stocks
AquaVenture extends long-stop date for Ghana plant acquisition to September 30 »

AquaVenture announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

17:22
06/22/18
06/22
17:22
06/22/18
17:22
Periodicals
Nissan chooses Thailand for hybrid's first export market, Nikkei reports »

Nissan has planned to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROV

Trovagene

$0.81

-0.0068 (-0.83%)

17:22
06/22/18
06/22
17:22
06/22/18
17:22
Hot Stocks
Trovagene CEO William Welch resigns, Dr. Thomas Adams named interim CEO »

Trovagene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$3.26

0.005 (0.15%)

17:19
06/22/18
06/22
17:19
06/22/18
17:19
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

$33.49

-0.15 (-0.45%)

17:19
06/22/18
06/22
17:19
06/22/18
17:19
Hot Stocks
Aecom to compete for $148.5M U.S. Army contract »

AECOM-Baker JV, Bryan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

17:17
06/22/18
06/22
17:17
06/22/18
17:17
Hot Stocks
Lockheed Martin awarded $175.3M U.S. Navy contract modification »

Lockheed Martin is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

17:16
06/22/18
06/22
17:16
06/22/18
17:16
Hot Stocks
Lockheed Martin awarded $1.12B U.S. Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

XLE

Energy Select Sector SPDR

$75.21

1.59 (2.16%)

, XLU

Utilities SPDR

$50.75

0.36 (0.71%)

17:14
06/22/18
06/22
17:14
06/22/18
17:14
General news
Week ending ETF Scorecard: Utilities and Real Estate advance, Industrials slump »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$75.21

1.59 (2.16%)

XLU

Utilities SPDR

$50.75

0.36 (0.71%)

IYR

DJ US Real Estate Index Fund

$80.69

0.56 (0.70%)

XLP

Consumer Staples Sector SPDR

$51.62

0.42 (0.82%)

XLY

Consumer Discretionary Sector SPDR

$111.34

-0.15 (-0.13%)

XLB

S&P Select Materials SPDR

$58.49

0.79 (1.37%)

XLF

Financial Select Sector

$27.07

-0.145 (-0.53%)

XLV

Health Care Select Sector SPDR

$84.91

0.35 (0.41%)

XLK

Technology Select Sector SPDR

$70.78

-0.24 (-0.34%)

XLI

Industrial Select Sector SPDR

$72.59

0.22 (0.30%)

GLD

SPDR Gold Trust

$120.33

0.27 (0.22%)

SLV

iShares Silver Trust

$15.49

0.135 (0.88%)

USO

United States Oil Fund

$14.02

0.71 (5.33%)

UNG

United States Natural Gas Fund

$23.87

-0.24 (-1.00%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.91

-0.015 (-0.02%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$113.99

0.105 (0.09%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.57

0.06 (0.05%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.11

0.03 (0.03%)

SHY

iShares 1-3 Year Treasury Bond

$83.30

0.005 (0.01%)

IWD

iShares Russell 1000 Value

$122.51

0.56 (0.46%)

IWF

iShares Russell 1000 Growth

$146.24

-0.2 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFNX

Pfenex

$5.43

0.14 (2.65%)

17:01
06/22/18
06/22
17:01
06/22/18
17:01
Hot Stocks
Pfenex set to join Russell 2000 Index »

Pfenex announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXE

Bellatrix Exploration

$1.00

-0.0101 (-1.00%)

17:01
06/22/18
06/22
17:01
06/22/18
17:01
Syndicate
Breaking Syndicate news story on Bellatrix Exploration »

Bellatrix Exploration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGI

Logitech

$44.24

0.25 (0.57%)

16:56
06/22/18
06/22
16:56
06/22/18
16:56
Initiation
Logitech initiated  »

Logitech initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$30.35

0.925 (3.14%)

16:51
06/22/18
06/22
16:51
06/22/18
16:51
Hot Stocks
Breaking Hot Stocks news story on PagSeguro Digital »

Point72 Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

APLS

Apellis

$21.75

-0.2 (-0.91%)

16:50
06/22/18
06/22
16:50
06/22/18
16:50
Conference/Events
Apellis to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$274.75

0.47 (0.17%)

16:50
06/22/18
06/22
16:50
06/22/18
16:50
Periodicals
SEC investigates whether companies rounded up earnings, WSJ reports »

The U.S. Securites and…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$274.75

0.47 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THRM

Gentherm

$38.20

-0.75 (-1.93%)

16:45
06/22/18
06/22
16:45
06/22/18
16:45
Conference/Events
Gentherm to hold a strategic update »

Strategic Update for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGTX

MeiraGTx

$11.86

-0.97 (-7.56%)

16:43
06/22/18
06/22
16:43
06/22/18
16:43
Hot Stocks
Breaking Hot Stocks news story on MeiraGTx »

Perceptive Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$86.80

0.51 (0.59%)

16:39
06/22/18
06/22
16:39
06/22/18
16:39
Conference/Events
Medtronic to hold an analyst and investor briefing »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

, FOX

21st Century Fox

$48.28

0.31 (0.65%)

16:35
06/22/18
06/22
16:35
06/22/18
16:35
Hot Stocks
21st Century Fox extends CFO John Nallen's employment contract to 2021 »

On June 22, 21st Century…

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

FOX

21st Century Fox

$48.28

0.31 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.